Clinical Trial Update: Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast [Phase 1]

View source ↗

Summary

A Phase I trial evaluating the combination of RAD001 (everolimus) with capecitabine in metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• RAD001 (everolimus)

Snippet

Sponsor: Stanford University | Conditions: Breast Cancer | Phase 1 | Status: TERMINATED